Halozyme Therapeutics Inc (FRA:RV7)
€ 45.9 0.41 (0.9%) Market Cap: 5.88 Bil Enterprise Value: 6.68 Bil PE Ratio: 15.94 PB Ratio: 13.52 GF Score: 85/100

Halozyme Therapeutics Inc Investor Business Forum and Long-Term Outlook Call Transcript

Jan 17, 2024 / 01:30PM GMT
Release Date Price: €33.14 (+6.12%)
Operator

Good morning. My name is Todd and I will be your conference operator today. At this time, I would like to welcome everyone to the Halozyme financial update call. Please note that this event is recorded. I am Tram Bui, vice president of investor relations and corporate communications. Please go ahead.

Helen Torley Halozyme Therapeutics
Inc. - President & CEO

Welcome to the here resign financial update call. Let me begin by briefly reviewing today's format. We will have a presentation followed by a Q&A session. During the presentation, we will be displaying a slide deck that will advance with each speaker's comments. On today's call, we will be making forward-looking statements as outlined on Slide 2. I would also refer you to our SEC filings for a full list of risks and uncertainties. During the call, both GAP and non gap financial measures will be discussed. Certain non gap or adjusted financial measures are reconciled with the comparable GAAP financial measures in the slide presentation. I will now turn the call over to Doctor Helen Torley, President

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot